BRAF and cancer: In addition, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) suggest that the BRAF gene to be evaluated prior making treatment decisions for patients with cancers (Allegra et al., 2009; Anderson, 2001).